Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck (MRK).

Key Takeaways Patritumab deruxtecan showed no overall survival benefit over chemotherapy in EGFR mutation-positive NSCLC patients. The drug demonstrated a slight progression-free survival advantage ...

Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan May 29, 2025 — 08:06 am EDT Written by RTTNews.com for RTTNews -> ...

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with Daiichi Sankyo (DSNKY). Read more here.

MRK’s deal with Daiichi involves three ADCs, namely patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan, which are across multiple solid tumor indications in different stages ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

Daiichi Sankyo and Merck entered into a global collaboration in October 2023 to jointly develop and commercialize patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug ...

Key Takeaways Patritumab deruxtecan, with or without letrozole, showed similar efficacy to chemotherapy in high-risk HR-positive, HER2-negative breast cancer, with lower severe side effects. The SOLTI ...